Introduction: Pharmacological options to address the imbalance between bone resorption
and accrual in osteoporosis include anti-resorptive and osteoanabolic agents. Unique …

Introduction: Osteoporosis is a common skeletal disease with serious consequences due to
osteoporotic fractures and high costs to society for post-fracture care. Most patients at high …

Osteoporosis is a disease with a significant disease burden worldwide, affecting more than
75 million people in the US, Europe and Japan. With an ageing population the incidence of …

Current osteoporosis medications reduce fractures significantly but have rare and serious
adverse effects (osteonecrosis of the jaw, atypical femoral fractures) that may limit their …

New anti-osteoporotic agents have been developed, potentially enriching the therapeutic
armamentarium. Currently available osteoanabolic therapies are the parathyroid hormone …

Although several effective therapies are available for the treatment of osteoporosis in
postmenopausal women and older men, there remains a need for the development of even …

Background There are many pharmaceutical interventions available to prevent osteoporotic
vertebral fractures in postmenopausal women, but the efficacy and safety of these drugs are …

During the past 2 decades, many interventions were proven effective in the management of
postmenopausal osteoporosis. The objective of an anti-osteoporosis treatment is to reduce …

Osteoporosis and fragility fractures are relevant health issues because of their impact in
terms of morbidity, mortality, and socioeconomic burden. Despite this alarming scenario …

Introduction: Osteoporosis is a chronic, skeletal disorder characterized by compromised
bone strength and increased risk of fractures, affecting up to 50% of postmenopausal …